Bobak Azamian, Tarsus CEO
July 25, 2023 11:23 AM EDT
Pharma
FDA+

Tar­sus scores first FDA ap­proval for treat­ment of red, itchy eyes caused by mites

Nicole DeFeudis

Editor

Tar­sus Phar­ma­ceu­ti­cals has se­cured the FDA’s first ap­proval to treat ir­ri­tat­ed eyes caused by tiny mites, a con­di­tion known as de­mod­ex …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­vo Nordisk’s Ca­griSe­ma shows 15.7% weight loss in sec­ond piv­otal tri­al

How blue­bird's buy­out of­fer went from $100M up­front to $29M

Sun Phar­ma to ac­quire Check­point Ther­a­peu­tics and its an­ti-PD-L1 an­ti­body

Ex­clu­sive: Dai­ichi Sankyo, John­son & John­son part­ner with RNA de­liv­ery start­up No­sis Bio

Min­eralys’ Phase 3 blood pres­sure pill da­ta sup­port po­ten­tial FDA ap­proval

sponsored

Obe­si­ty drug de­vel­op­ment—still room to grow

A service from the Financial Times